Rivaroxaban therapy, false-positive lupus anticoagulant screening results, and confirmatory assay results

Lab Medicine

Volumn 47, Issue 4, 2016, Pages 275-278

  Murer, Lauren M ^a   Pirruccello, Samuel J ^a   Koepsell, Scott A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antiphospholipid syndrome; Lupus anticoagulant; Rivaroxaban

Indexed keywords

LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; IMMUNOLOGIC FACTOR; PHOSPHOLIPID;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DIAGNOSTIC TEST; DILUTION; FALSE POSITIVE RESULT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RUSSELL VIPER VENOM TIME; SCREENING; THROMBIN TIME; ADOLESCENT; ADULT; AGED; BLOOD; FEMALE; MALE; MASS SCREENING; MIDDLE AGED; PROCEDURES; SYSTEMIC LUPUS ERYTHEMATOSUS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FACTOR XA INHIBITORS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MASS SCREENING; MIDDLE AGED; PHOSPHOLIPIDS; RIVAROXABAN;

EID: 84994318182     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1093/labmed/lmw029     Document Type: Article

References (13)

1. Wilson W, Gharavi A, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum. 1999;42:1309-1311.
2. Miyakis S, Locksin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
3. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med. 2002;126:1424-1429.
4. Genzen J, Miller J. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing. Am J Clin Pathol. 2005;124:586-593.
5. Gosselin R, King J, Janatpur K, et al. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med. 2004;128: 1142-1145.
6. Olah Z, Szarvas M, Bereczky Z, et al. Direct thrombin inhibitors and factor Xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant. Arch Pathol Lab Med. 2013;137:967-973.
7. CLSI. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline CLSI document H60-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
8. Sangle N, Smock K. Antiphospholipid antibody syndrome. Arch Pathol Lab Med. 2011;135:1092-1096.
9. Wisløff F, Jacobsen E, Liestøl S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Research. 2002;108:263-271.
10. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7:1737-1740.
11. Merriman E, Kaplan Z, Butler J, et al. Rivaroxaban and false positive lupus anticoagulant testing. J Thromb Haemost. 2011;105:1-2.
12. Van Os GMA, de Laat B, Kamphuisen P, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011;9:1657-1659.
13. Graff J, von Henting N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47:1398-1407.